Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy?

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Heat shock protein 90 (HSP90) is crucial for oncogenic protein stability and function.
• HSP90 is overexpressed in cancer cells, making it a prime target for cancer therapy.
• HSP90 inhibitors have demonstrated anti-neoplastic activity in preclinical models.

Purpose of the Study:

• To review the role of HSP90 in tumor angiogenesis.
• To delineate the anti-angiogenic effects of HSP90 inhibitors.
• To explore the impact of HSP90 inhibition on angiogenic signaling pathways.

Main Methods:

• Literature review focusing on HSP90, angiogenesis, and cancer therapy.
• Analysis of studies investigating HSP90 inhibitors' effects on endothelial cells and tumor vascularization.
• Examination of signaling pathways such as PI-3K/Akt/eNOS and VEGFR-2.

Main Results:

• HSP90 inhibitors exhibit direct anti-angiogenic effects by targeting the PI-3K/Akt/eNOS pathway and down-regulating VEGFR-2.
• HSP90 inhibition leads to indirect anti-angiogenic effects by reducing pro-angiogenic factors from tumor cells.
• HSP90 inhibitors demonstrate dual action: targeting tumor cells and inhibiting tumor vascularization.

Conclusions:

• HSP90 is a significant target for cancer therapy due to its role in both oncogenic signaling and angiogenesis.
• HSP90 inhibitors offer a dual therapeutic strategy by directly killing cancer cells and inhibiting tumor growth via anti-angiogenesis.
• Further research into HSP90 inhibitors could lead to novel combination therapies for enhanced cancer treatment.